Download PDF
Semin Thromb Hemost
DOI: 10.1055/a-2528-5425
Review Article

Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review

Angela Napolitano
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Luca Spiezia 
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Marta Biolo
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Claudia Maria Radu
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Serena Toffanin
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Elena Campello
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
,
Paolo Simioni
1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Anti-platelet factor 4 (PF4) antibody-mediated disorders are a heterogeneous group of diseases characterized by the presence of highly pathogenic immunoglobulins G directed against PF4 and/or PF4/heparin complexes. These antibodies are able to activate platelets, neutrophils, and monocytes, thus resulting in thrombocytopenia and a hypercoagulable state. Five different forms of anti-PF4 antibody-mediated disorders have been identified: (1) classic heparin-induced thrombocytopenia (HIT) mediated by heparin and certain polyanionic drugs; (2) autoimmune HIT characterized by the presence of anti-PFA/polyanion antibodies that can strongly activate platelets even in the absence of heparin; (3) spontaneous HIT characterized by thrombocytopenia and thrombosis without proximate exposure to heparin, with two subtypes: (a) post-total knee arthroplasty and cardiac surgery using cardiopulmonary bypass or extracorporeal membrane oxygenation and (b) postinfections; (4) vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by thrombocytopenia, arterial and venous thrombosis, or secondary hemorrhage after receiving adenoviral vector vaccines for coronavirus disease 2019; (5) VITT-like disorders triggered by adenoviral infections. Although extremely rare and largely unknown, there has been growing interest in the VITT syndrome in recent years due to its clinical relevance. Timely detection of these antibodies is crucial for the diagnosis and treatment of anti-PF4 antibody-mediated disorders, via anti-PF4 antibody immunoassays using several antibody capture systems (e.g., enzyme-linked immunosorbent assay-based, particle gel, turbidimetry) and functional assays (e.g., serotonin release assay or heparin-induced platelet activation). We aimed to present the latest on laboratory findings, clinical characteristics, and therapeutic approaches for anti-PF4 antibody-mediated disorders.

Keywords

anti-PF4 antibody-mediated disorders - heparin-induced thrombocytopenia - VITT

Authors' Contributions

A.N. and L.S.: writing—original draft; M.B.: writing—“laboratory findings;” C.M.R. and S.T.: lab experiments—[Fig. 5]; E.C. and P.S.: writing—review and editing.




Publication History

Accepted Manuscript online:
30 January 2025

Article published online:
19 February 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Greinacher A, Schönborn L, Siegerist F. et al. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol 2022; 59 (02) 97-107
    CrossrefPubMedSearch in Google Scholar
  • 2 Greinacher A, Holtfreter B, Krauel K. et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118 (05) 1395-1401
    CrossrefPubMedSearch in Google Scholar
  • 3 Hursting MJ, Pai PJ, McCracken JE. et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134 (05) 774-780
    CrossrefPubMedSearch in Google Scholar
  • 4 Morgan FJ, Begg GS, Chesterman CN. Complete covalent structure of human platelet factor 4. Thromb Haemost 1980; 42 (05) 1652-1660
    PubMedSearch in Google Scholar
  • 5 Krauel K, Pötschke C, Weber C. et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117 (04) 1370-1378
    CrossrefPubMedSearch in Google Scholar
  • 6 Warkentin TE. Platelet-activating anti-PF4 disorders: an overview. Semin Hematol 2022; 59 (02) 59-71
    CrossrefPubMedSearch in Google Scholar
  • 7 Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995; 91 (08) 2188-2194
    CrossrefPubMedSearch in Google Scholar
  • 8 Demma L, Levy JH. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg 2012; 115 (06) 1273-1278
    CrossrefPubMedSearch in Google Scholar
  • 9 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Dupuy A, Liu X, Tieng J. et al. Endothelial cell activation enhances thromboinflammation in VITT. Blood 2022; 140 (Suppl. 01) 1656-1657
    CrossrefPubMedSearch in Google Scholar
  • 11 Rauova L, Poncz M, McKenzie SE. et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105 (01) 131-138
    CrossrefPubMedSearch in Google Scholar
  • 12 Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138 (01) 22-31
    CrossrefPubMedSearch in Google Scholar
  • 13 Warkentin TE, How I. How I diagnose and manage HIT. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 143-149
    CrossrefPubMedSearch in Google Scholar
  • 14 Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med 2021; 10 (04) 683
    CrossrefPubMedSearch in Google Scholar
  • 15 Arepally GM. Heparin-induced thrombocytopenia. Blood 2017; 129 (21) 2864-2872
    CrossrefPubMedSearch in Google Scholar
  • 16 Liu Z, Li L, Zhang H. et al. Platelet factor 4(PF4) and its multiple roles in diseases. Blood Rev 2024; 64: 101155
    CrossrefPubMedSearch in Google Scholar
  • 17 Greinacher A. Clinical Practice. Heparin-induced thrombocytopenia. N Engl J Med 2015; 373 (03) 252-261
    CrossrefPubMedSearch in Google Scholar
  • 18 Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol 2019; 41 (Suppl. 01) 15-25
    CrossrefPubMedSearch in Google Scholar
  • 19 Cuker A, Arepally GM, Chong BH. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018; 2 (22) 3360-3392
    CrossrefPubMedSearch in Google Scholar
  • 20 Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia. J Clin Med 2020; 9 (04) 1226
    CrossrefPubMedSearch in Google Scholar
  • 21 Warkentin TE, Davidson BL, Büller HR. et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140 (02) 366-373
    CrossrefPubMedSearch in Google Scholar
  • 22 Favaloro EJ, Pasalic L, Henry B, Lippi G. Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia. Pathology 2022; 54 (03) 254-261
    CrossrefPubMedSearch in Google Scholar
  • 23 Husseinzadeh HD, Gimotty PA, Pishko AM, Buckley M, Warkentin TE, Cuker A. Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. J Thromb Haemost 2017; 15 (06) 1203-1212
    CrossrefPubMedSearch in Google Scholar
  • 24 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; 121 (12) 1622-1627
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Warkentin TE, Arnold DM, Sheppard JI, Moore JC, Kelton JG, Nazy I. Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT. J Thromb Haemost 2023; 21 (08) 2268-2276
    CrossrefPubMedSearch in Google Scholar
  • 26 Warkentin TE. Heparin-induced thrombocytopenia (and autoimmune heparin-induced thrombocytopenia): an illustrious review. Res Pract Thromb Haemost 2023; 7 (08) 102245
    CrossrefPubMedSearch in Google Scholar
  • 27 Warkentin TE, Nazy I, Sheppard JI, Smith JW, Kelton JG, Arnold DM. Serotonin-release assay-negative heparin-induced thrombocytopenia. Am J Hematol 2020; 95 (01) 38-47
    CrossrefPubMedSearch in Google Scholar
  • 28 Vayne C, Rollin J, Gruel Y. et al. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385 (04) 376-378
    CrossrefPubMedSearch in Google Scholar
  • 29 Greinacher A, Selleng K, Palankar R. et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138 (22) 2256-2268
    CrossrefPubMedSearch in Google Scholar
  • 30 Lee CSM, Liang HPH, Connor DE. et al. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Adv 2022; 6 (11) 3494-3506
    CrossrefPubMedSearch in Google Scholar
  • 31 Lee CSM, Powell MC, Chen VM. Whole blood procoagulant platelet flow cytometry protocol for heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT) testing. Methods Mol Biol 2023; 2663: 441-461
    CrossrefPubMedSearch in Google Scholar
  • 32 Zlamal J, Aliotta A, Alberio L, Chen V, Bakchoul T, Platelet SSC. SSC Platelet Immunology of the ISTH. Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2024; 22 (03) 860-868
    CrossrefPubMedSearch in Google Scholar
  • 33 Tomer A, Masalunga C, Abshire TC. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am J Hematol 1999; 61 (01) 53-61
    CrossrefPubMedSearch in Google Scholar
  • 34 Skornova I, Simurda T, Stanciakova L. et al. A functional assay for the determination of heparin-induced thrombocytopenia via flow cytometry. Diagnostics (Basel) 2023; 13 (18) 3019
    CrossrefPubMedSearch in Google Scholar
  • 35 Tardy-Poncet B, Montmartin A, Piot M. et al; On Behalf Of The Gfht-Hit Study Group. Functional flow cytometric assay for reliable and convenient heparin-induced thrombocytopenia diagnosis in daily practice. Biomedicines 2021; 9 (04) 332
    CrossrefPubMedSearch in Google Scholar
  • 36 Runser A, Schaning C, Allemand F, Amiral J. An optimized and standardized rapid flow cytometry functional method for heparin-induced thrombocytopenia. Biomedicines 2021; 9 (03) 296
    CrossrefPubMedSearch in Google Scholar
  • 37 Padmanabhan A, Jones CG, Bougie DW. et al. A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT. Thromb Haemost 2015; 114 (06) 1322-1323
    PubMedSearch in Google Scholar
  • 38 Kanack AJ, Singh B, George G. et al. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol 2022; 97 (05) 519-526
    CrossrefPubMedSearch in Google Scholar
  • 39 Samuelson Bannow B, Warad DM, Jones CG. et al. A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. Blood 2021; 137 (08) 1082-1089
    CrossrefPubMedSearch in Google Scholar
  • 40 Handtke S, Wolff M, Zaninetti C. et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood 2021; 137 (26) 3656-3659
    CrossrefPubMedSearch in Google Scholar
  • 41 Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596 (7873): 565-569
    CrossrefPubMedSearch in Google Scholar
  • 42 Brown JA, Aranda-Michel E, Kilic A. et al. Outcomes with heparin-induced thrombocytopenia after cardiac surgery. Ann Thorac Surg 2021; 112 (02) 487-493
    CrossrefPubMedSearch in Google Scholar
  • 43 Pishko AM, Cuker A. Heparin-induced thrombocytopenia and cardiovascular surgery. Hematology (Am Soc Hematol Educ Program) 2021; 2021 (01) 536-544
    CrossrefPubMedSearch in Google Scholar
  • 44 Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76 (06) 2121-2131
    CrossrefPubMedSearch in Google Scholar
  • 45 Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Clin Med 2023; 12 (21) 6921
    CrossrefPubMedSearch in Google Scholar
  • 46 Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15 (11) 2099-2114
    CrossrefPubMedSearch in Google Scholar
  • 47 Manji F, Warkentin TE, Sheppard JI, Lee A. Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets 2020; 31 (01) 124-127
    CrossrefPubMedSearch in Google Scholar
  • 48 Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost 2017; 1 (01) 134-137
    CrossrefPubMedSearch in Google Scholar
  • 49 Roberge G, Tritschler T, MacGillivray C, Dufresne L, Nagpal SK, Scarvelis D. Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair: a case report. J Thromb Thrombolysis 2020; 50 (03) 674-677
    CrossrefPubMedSearch in Google Scholar
  • 50 Arcinas LA, Manji RA, Hrymak C, Dao V, Sheppard JI, Warkentin TE. Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Transfusion 2019; 59 (06) 1924-1933
    CrossrefPubMedSearch in Google Scholar
  • 51 Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf 2014; 13 (01) 25-43
    CrossrefPubMedSearch in Google Scholar
  • 52 Dougherty JA, Yarsley RL. Intravenous immune globulin (IVIG) for treatment of autoimmune heparin-induced thrombocytopenia: a systematic review. Ann Pharmacother 2021; 55 (02) 198-215
    CrossrefPubMedSearch in Google Scholar
  • 53 Makita N, Ohara T, Tsuji Y. et al. Early high-dose intravenous immunoglobulin for refractory heparin-induced thrombocytopenia with stroke: two case reports. J Stroke Cerebrovasc Dis 2023; 32 (04) 107032
    CrossrefPubMedSearch in Google Scholar
  • 54 Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol 2019; 12 (08) 685-698
    CrossrefPubMedSearch in Google Scholar
  • 55 Kudo Y, Suzuki K, Maezawa S, Seo R, Irinoda T. High-dose immunoglobulin therapy for multiple thromboembolism in persisting heparin-induced thrombocytopenia. Cureus 2024; 16 (03) e55747
    PubMedSearch in Google Scholar
  • 56 Batool A, Chaudhry S, Javaid A, Kenney A. Autoimmune heparin-induced thrombocytopenia: a diagnostic and management challenge after transcatheter aortic valve replacement. Cureus 2023; 15 (09) e45453
    PubMedSearch in Google Scholar
  • 57 Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb Res 2021; 204: 40-51
    CrossrefPubMedSearch in Google Scholar
  • 58 Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT?. J Thromb Haemost 2008; 6 (09) 1598-1600
    CrossrefPubMedSearch in Google Scholar
  • 59 Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. J Thromb Haemost 2009; 7 (03) 499-501
    CrossrefPubMedSearch in Google Scholar
  • 60 Mallik A, Carlson KB, DeSancho MT. A patient with 'spontaneous' heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis 2011; 22 (01) 73-75
    CrossrefPubMedSearch in Google Scholar
  • 61 Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W, McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost 2013; 109 (04) 669-675
    Thieme ConnectPubMedSearch in Google Scholar
  • 62 Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014; 123 (23) 3651-3654
    CrossrefPubMedSearch in Google Scholar
  • 63 Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med 2015; 372 (05) 492-494
    CrossrefPubMedSearch in Google Scholar
  • 64 Elshoury A, Khedr M, Abousayed MM, Mehdi S. Spontaneous heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages and pulmonary embolism after total knee arthroplasty. Arthroplast Today 2015; 1 (03) 69-71
    CrossrefPubMedSearch in Google Scholar
  • 65 Baker K, Lim MY. Spontaneous heparin-induced thrombocytopenia and venous thromboembolism following total knee arthroplasty. Case Rep Hematol 2017; 2017: 4918623
    PubMedSearch in Google Scholar
  • 66 Ly BA, Quintero L. Adrenal insufficiency from unilateral adrenal hemorrhage in a patient on. Rivaroxaban thromboprophylaxis. AACE Clin Case Rep 2019; 5 (01) e70-e72
    CrossrefPubMedSearch in Google Scholar
  • 67 Alidoost M, Soomro R, Gubeladze A. et al. Rivaroxaban related bilateral adrenal hemorrhage: a rare complications of direct oral anticoagulants - a case reports. Am J Case Rep 2019; 20: 1607-1611
    CrossrefPubMedSearch in Google Scholar
  • 68 Mohanty E, Nazir S, Sheppard JI, Forman DA, Warkentin TE. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. J Thromb Haemost 2019; 17 (05) 841-844
    CrossrefPubMedSearch in Google Scholar
  • 69 Swarup S, Kopel J, Yendala R, Thirumala S, Quick DP. Spontaneous heparin induced thrombocytopenia (HIT) following curettage and bone graft of femur in a patient with monostotic fibrous dysplasia. Thromb Res 2020; 196: 75-77
    CrossrefPubMedSearch in Google Scholar
  • 70 Hwang SR, Wang Y, Weil EL, Padmanabhan A, Warkentin TE, Pruthi RK. Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets 2021; 32 (07) 936-940
    CrossrefPubMedSearch in Google Scholar
  • 71 Yoshida R, Tanaka A, Yoshioka N, Yokote J. Heparin 'flush' induced thrombocytopenia triggered by total hip replacement: a case report. Eur Heart J Case Rep 2020; 4 (02) 1-5
    CrossrefPubMedSearch in Google Scholar
  • 72 Hornick J, Ayafor G. Spontaneous heparin induced thrombocytopenia: when a post-op pulmonary embolism isn't just a post-op pulmonary embolism. J Am Coll Cardiol 2020; 75: 3179
    CrossrefPubMedSearch in Google Scholar
  • 73 Saengboon S, Chinthammitr Y, Kanitsap N. Spontaneous heparin-induced thrombocytopaenia with adrenal haemorrhage following orthopaedic surgery: a case report and literature review. BMJ Case Rep 2021; 14 (11) e245385
    CrossrefPubMedSearch in Google Scholar
  • 74 Olevsky OM, Rosove MH. “Spontaneous” heparin-induced thrombocytopenia and thrombosis after total knee arthroplasty: a report of 2 cases. Arthroplast Today 2021; 9: 50-52
    CrossrefPubMedSearch in Google Scholar
  • 75 Krauel K, Weber C, Brandt S. et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012; 120 (16) 3345-3352
    CrossrefPubMedSearch in Google Scholar
  • 76 Grigorian A, Schubl S, Barrios Jr C. et al. Association of heparin-induced thrombocytopenia with bacterial infection in trauma patients. JAMA Surg 2018; 153 (10) 964-965
    CrossrefPubMedSearch in Google Scholar
  • 77 Rigamonti E, Bonora T, Ventresca M, Cippà P. Heparin-induced thrombocytopenia following Shiga-toxin-associated hemolytic uremic syndrome: a case report. J Med Case Rep 2022; 16 (01) 384
    CrossrefPubMedSearch in Google Scholar
  • 78 Sugioka S, Doi Y, Ishihara T. et al. A case of heparin-induced thrombocytopenia (HIT) triggered by methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ren Replace Ther 2016; 2: 62
    CrossrefPubMedSearch in Google Scholar
  • 79 Olah Z, Kerenyi A, Kappelmayer J, Schlammadinger A, Razso K, Boda Z. Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure. Platelets 2012; 23 (06) 495-498
    CrossrefPubMedSearch in Google Scholar
  • 80 Becker CJ, Heston AL, Carrera JF. Spontaneous heparin-induced thrombocytopenia presenting as acute ischemic stroke. Neurol Clin Pract 2021; 11 (06) e918-e920
    CrossrefPubMedSearch in Google Scholar
  • 81 Kwan C, Reimers J, o'Gorman C, Bird R, Brown H. Multiterritorial strokes in the setting of spontaneous heparin-induced thrombocytopaenia syndrome. BMJ Case Rep 2022; 15 (02) e244143
    CrossrefPubMedSearch in Google Scholar
  • 82 Okata T, Miyata S, Miyashita F, Maeda T, Toyoda K. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: atypical clinical features with heparin-dependent platelet activating antibodies. Platelets 2015; 26 (06) 602-607
    CrossrefPubMedSearch in Google Scholar
  • 83 Irani M, Siegal E, Jella A, Aster R, Padmanabhan A. Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia. Transfusion 2019; 59 (03) 931-934
    CrossrefPubMedSearch in Google Scholar
  • 84 Newton F, Glaser K, Reeves J, Sheperd L, Ray B. Refractory heparin-induced thrombocytopenia in a patient with subarachnoid hemorrhage-a clinical conundrum. Neurohospitalist 2021; 11 (04) 360-364
    CrossrefPubMedSearch in Google Scholar
  • 85 Perrin J, Barraud D, Toussaint-Hacquard M, Bollaert PE, Lecompte T. Rapid onset heparin-induced thrombocytopenia (HIT) without history of heparin exposure: a new case of so-called 'spontaneous' HIT. Thromb Haemost 2012; 107 (04) 795-797
    Thieme ConnectPubMedSearch in Google Scholar
  • 86 Ueland T, Hausberg I, Mørtberg TV. et al. Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets 2022; 33 (04) 640-644
    CrossrefPubMedSearch in Google Scholar
  • 87 Pascreau T, Ballester MC, Van Dreden P. et al. The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis. Clin Chem Lab Med 2021; 59 (11) e405-e408
    CrossrefPubMedSearch in Google Scholar
  • 88 Piccin A, Mullin B, Brown A, Benson G. The lack of anti-PF4 antibodies in convalescent plasma from COVID-19 infected blood donor. Transfus Med 2023; 33 (03) 272-273
    CrossrefPubMedSearch in Google Scholar
  • 89 Shiuan E, Sharma D, Ely EW, Moodabagil N, Tillman BF. Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection. J Thromb Thrombolysis 2022; 54 (02) 367-371
    CrossrefPubMedSearch in Google Scholar
  • 90 Pai M. Epidemiology of VITT. Semin Hematol 2022; 59 (02) 72-75
    CrossrefPubMedSearch in Google Scholar
  • 91 See I, Lale A, Marquez P. et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann Intern Med 2022; 175 (04) 513-522
    CrossrefPubMedSearch in Google Scholar
  • 92 de Buhr N, Baumann T, Werlein C. et al. Insights into immunothrombotic mechanisms in acute stroke due to vaccine-induced immune thrombotic thrombocytopenia. Front Immunol 2022; 13: 879157
    CrossrefPubMedSearch in Google Scholar
  • 93 Kanack AJ, Padmanabhan A. Vaccine-induced immune thrombotic thrombocytopenia. Best Pract Res Clin Haematol 2022; 35 (03) 101381
    CrossrefPubMedSearch in Google Scholar
  • 94 Craven B, Lester W, Boyce S. et al. Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood 2022; 139 (16) 2553-2560
    CrossrefPubMedSearch in Google Scholar
  • 95 Asif S, Kesireddy M, Koepsell SA, Gonzalez-Castellon MA, Gundabolu K, Baljevic M. Cerebral venous sinus thrombosis due to thrombosis with thrombocytopenia syndrome following Ad26.COV2.S: a first real-world case report of a male subject. Neurohospitalist 2022; 12 (02) 346-351
    CrossrefPubMedSearch in Google Scholar
  • 96 Cines DB, Greinacher A. Vaccine-induced immune thrombotic thrombocytopenia. Blood 2023; 141 (14) 1659-1665
    CrossrefPubMedSearch in Google Scholar
  • 97 Rzymski P, Perek B, Flisiak R. Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism. Vaccines (Basel) 2021; 9 (06) 559
    CrossrefPubMedSearch in Google Scholar
  • 98 Chen QT, Liu Y, Chen YC. et al. Case report: vaccine-induced immune thrombotic thrombocytopenia complicated by acute cerebral venous thrombosis and hemorrhage after AstraZeneca vaccines followed by Moderna COVID-19 vaccine booster and surgery. Front Neurol 2022; 13: 989730
    CrossrefPubMedSearch in Google Scholar
  • 99 Savulescu F, Cirlan C, Iordache-Petrescu MI, Iordache M, Petrescu AB, Blajut C. Portal vein and mesenteric artery thrombosis following the administration of an Ad26.COV2-S vaccine-first case from Romania: a case report. Vaccines (Basel) 2022; 10 (11) 1950
    CrossrefPubMedSearch in Google Scholar
  • 100 Yelne P, Kabra R, Mathurkar S, Gaidhane SA, Acharya S, Kumar S. Relationship between vaccination and immune thrombotic thrombocytopenia: coincidental or causal?. Cureus 2022; 14 (08) e28560
    PubMedSearch in Google Scholar
  • 101 Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci 2021; 428: 117607
    CrossrefPubMedSearch in Google Scholar
  • 102 MacNeil JR, Su JR, Broder KR. et al. Updated recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (17) 651-656
    CrossrefPubMedSearch in Google Scholar
  • 103 Congiu T, Fanni D, Piras M. et al. Ultrastructural findings of lung injury due to vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study. Eur Rev Med Pharmacol Sci 2022; 26 (01) 270-277
    PubMedSearch in Google Scholar
  • 104 Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). J Leukoc Biol 2022; 111 (03) 725-734
    CrossrefPubMedSearch in Google Scholar
  • 105 McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun 2021; 121: 102662
    CrossrefPubMedSearch in Google Scholar
  • 106 Dabbiru VAS, Müller L, Schönborn L, Greinacher A. Vaccine-induced immune thrombocytopenia and thrombosis (VITT)-insights from clinical cases, in vitro studies and murine models. J Clin Med 2023; 12 (19) 6126
    CrossrefPubMedSearch in Google Scholar
  • 107 Schönborn L, Greinacher A. Longitudinal aspects of VITT. Semin Hematol 2022; 59 (02) 108-114
    CrossrefPubMedSearch in Google Scholar
  • 108 Johansen S, Laegreid IJ, Ernstsen SL. et al. Thrombosis and thrombocytopenia after HPV vaccination. J Thromb Haemost 2022; 20 (03) 700-704
    CrossrefPubMedSearch in Google Scholar
  • 109 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
    CrossrefPubMedSearch in Google Scholar
  • 110 Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood 2021; 138 (04) 293-298
    CrossrefPubMedSearch in Google Scholar
  • 111 Greinacher A, Langer F, Makris M. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: response to comment from Yamada et al. J Thromb Haemost 2022; 20 (02) 542-543
    CrossrefPubMedSearch in Google Scholar
  • 112 Oldenburg J, Klamroth R, Langer F. et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021; 41 (03) 184-189
    Thieme ConnectPubMedSearch in Google Scholar
  • 113 Nazy I, Sachs UJ, Arnold DM. et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on platelet immunology. J Thromb Haemost 2021; 19 (06) 1585-1588
    CrossrefPubMedSearch in Google Scholar
  • 114 Favaloro EJ, Pasalic L, Lippi G. Antibodies against platelet factor 4 and their associated pathologies: from HIT/HITT to spontaneous HIT-like syndrome, to COVID-19, to VITT/TTS. Antibodies (Basel) 2022; 11 (01) 7
    CrossrefPubMedSearch in Google Scholar
  • 115 Scutelnic A, Brodard J, Kremer Hovinga JA, Arnold M, Heldner MR. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia—a narrative review. Clin Transl Neurosci 2022; 6: 11
    CrossrefPubMedSearch in Google Scholar
  • 116 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
    CrossrefPubMedSearch in Google Scholar
  • 117 Greinacher A, Langer F, Makris M. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost 2022; 20 (01) 149-156
    CrossrefPubMedSearch in Google Scholar
  • 118 Rizk JG, Gupta A, Sardar P. et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol 2021; 6 (12) 1451-1460
    CrossrefPubMedSearch in Google Scholar
  • 119 Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med 2015; 373 (07) 642-655
    CrossrefPubMedSearch in Google Scholar
  • 120 Baker AT, Boyd RJ, Sarkar D. et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv 2021; 7 (49) eabl8213
    CrossrefPubMedSearch in Google Scholar
  • 121 Schönborn L, Esteban O, Wesche J. et al. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood 2023; 142 (26) 2305-2314
    CrossrefPubMedSearch in Google Scholar
  • 122 Greinacher A. Me or not me? The danger of spontaneity. Blood 2014; 123 (23) 3536-3538
    CrossrefPubMedSearch in Google Scholar
  • 123 Greinacher A, Langer F, Schönborn L. et al. Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica 2022; 107 (05) 1219-1221
    CrossrefPubMedSearch in Google Scholar
  • 124 Warkentin TE, Baskin-Miller J, Raybould AL. et al. Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies. N Engl J Med 2023; 389 (06) 574-577
    CrossrefPubMedSearch in Google Scholar
  • 125 Campello E, Biolo M, Simioni P. More on adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies. N Engl J Med 2023; 389 (18) 1729
    CrossrefPubMedSearch in Google Scholar
  • 126 Khan Z, Patel I, Gardner T. et al. Recurrent stent thrombosis following myocardial infarction associated with VITT-like antibodies. JACC Case Rep 2024; 29 (05) 102234
    CrossrefPubMedSearch in Google Scholar
  • 127 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
    Thieme ConnectPubMedSearch in Google Scholar
  • 128 Lindhoff-Last E, Schönborn L, Zaninetti C, Warkentin TE, Greinacher A. Rescue therapy in chronic prothrombotic autoimmune anti-PF4 disorder. N Engl J Med 2023; 389 (14) 1339-1341
    CrossrefPubMedSearch in Google Scholar
  • 129 Müller L, Dabbiru VAS, Schönborn L, Greinacher A. Therapeutic strategies in FcγIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Expert Opin Pharmacother 2024; 25 (03) 281-294
    CrossrefPubMedSearch in Google Scholar
  • 130 Favaloro EJ, Henry BM, Lippi G. The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19. Int J Lab Hematol 2021; 43 (04) 547-558
    CrossrefPubMedSearch in Google Scholar
  • 131 Bennett A, Choi PY, Tan CW. Platelet factor 4 immune disease: medical emergencies that look like heparin-induced thrombocytopenia. Intern Med J 2024; 54 (12) 2072-2076
    CrossrefPubMedSearch in Google Scholar
  • 132 Wang JJ, Schönborn L, Warkentin TE. et al. Antibody fingerprints linking adenoviral anti-PF4 disorders. N Engl J Med 2024; 390 (19) 1827-1829
    CrossrefPubMedSearch in Google Scholar
  • 133 Nilius H, Hamzeh-Cognasse H, Hastings J. et al. Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia. Blood Adv 2024; 8 (11) 2825-2834
    CrossrefPubMedSearch in Google Scholar